Floatz logo

CITALOPRAM

Borderline Personality Disorder

Columbia Northwest PharmaceuticalsSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Borderline Personality Disorder cohort.

Asset / SponsorPhaseRating
Zelapar
Mood and Anxiety Research, Inc
Phase 3BB
LITHIUM, ELEMENTAL
Columbia Northwest Pharmaceuticals
Phase 2B
TEONANACATL
University of Chicago
Phase 2B
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Joshua Rosenblat
Phase 2CCC
MIDAZOLAM
Joshua Rosenblat
Phase 2CCC

View all 9 →

Same molecule, other indications

CITALOPRAM is also rated in:

Bipolar I DisorderDormant
BBB
Indicative ·
77 / 100
View asset →
bipolar disorderDormant
BBB
Indicative ·
74 / 100
View asset →
depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →